Various pre-erythrocyte malaria vaccines are currently in clinical development, among which the Adenovirus serotype 35 based circumsporozoite (CS) vaccine produced on PER.C6 ® cells. Although the immunological correlate of protection against Malaria remains to be established, the CS antibody titer is a good marker for evaluation of candidate vaccines. Here we describe the validation of an anti Plasmodium falciparum circumsporozoite antibody ELISA based on the binding of antibodies to a peptide antigen mimicking the CS repeat region. The inter-assay variability was determined to be below 15% coefficient of variation (CV), sensitivity was sufficient to detect low antibody titers in subjects from endemic regions. Antibody titers were in agreement with total antibody responses to the whole CS protein, and to the whole parasite. Due to its simplicity and high performance, the ELISA is an easy and rapid method for assessment of preerythrocyte malaria vaccines based on CS.
Introduction
Malaria remains the most lethal infectious disease, killing nearly one million people each year. The development of a protective vaccine against malaria is considered high priority in order to prevent the disease (WHO: http://www.who.int/mediacentre/ news/notes/2006/np35/en/print.html),(MVI: http://www.malariavaccineroadmap.net/pdfs/ vision_document.pdf). Although the feasibility of a Malaria vaccine was demonstrated using irradiated sporozoites more than 30 years ago (3) , an effective malaria vaccine has not been generated as yet. The protective effect of irradiated sporozoites is likely due to a protective antibody response. Immunological studies over the following decades however have indicated that both antibodies as well as T cells are required for protection against infection with malaria parasites.
Adenoviral vectors have been proven highly efficient in inducing both cellular and humoral immune responses in various disease models (1, 16, 20) . Therefore recombinant adenoviral vectors are considered as a potential vaccine to prevent malaria disease. We have developed such candidate malaria vaccine based on adenovirus serotype 35 (Ad35) expressing a Pf circumsporozoite (CS) transgene (Ad35.CS) which is produced on PER.C6 ® cells. This vaccine induced strong immune responses in mice (17) , and rhesus macaques (14, 18) . Although heterologous prime boost vaccine strategies are likely required to prevent malaria infection (12) , Ad35 is proposed as an important component of such combination. Following the successful preclinical investigations on Ad35.CS, a clinical phase I trial has started in the US. The primary objective of this phase I study is to show safety and tolerability, and the secondary objective is to explore the immunogenicity of the vaccine by measuring T cell responses and antibody responses.
In this report we describe the development and validation of an antibody ELISA that determines the antibody titer in human serum against CS induced by the vaccine, in order to support the secondary objective. Although the correlates of protection against malaria are not determined yet, the antibody assay described here is required to provide an accurate indication of the humoral immunogenicity of the vaccine. Therefore we selected the immunodominant epitope in the CS antigen as target for the antibody assay in order to detect the majority of human responses induced by the vaccine. Since the repeat region on August 27, 2017 by guest http://cvi.asm.org/ of CS is the immunodominant region for B cell epitopes (22) (23) (24) , and antibodies against the NANP 3 epitope in the repeat region reflects exposure to natural P.falciparum infection (25) , it is assumed that the antibodies directed to this region correlate with the total amount of anti CS antibodies. The (NANP) 6 C peptide as described by Stoute (19) is the optimal representation of the repeat region, and was selected as capture antigen in our assay. In general, an antibody ELISA would be based on the complete antigen of interest.
The CS protein however, is not readily available to the scientific community, and recombinant CS proteins from different sources may hamper the comparability of results between different laboratories. Using a synthetic peptide as target antigen, could facilitate the comparability between laboratories, since the antigen quality is much easier to guarantee for a peptide than for a recombinant protein.
Here we describe the development of the CS antibody ELISA to determine the humoral immunogenicity of Ad35.CS in human subjects, and its validation as a robust, and reproducible assay to support clinical vaccine development.
Materials & methods

CS antibody ELISA protocol
The peptide (NANP) 6 C comprising 6 repeats of NANP mimics a part of the repeat sequence of Pf CS (4, 19) , and this peptide was used as capture antigen to bind CS specific antibodies. The peptide was obtained from Pepscan (Lelystad, The Netherlands) at a purity of 90%. The peptide was coated at a concentration of 2 µg/ml in 0.05M Carbonate buffer at 2-8 °C, ON or for a maximum of 3 days. Reference serum, serum samples, and internal controls were diluted in PBS + 2% gelatin + 1% human serum (dilution buffer), and incubated for 1 hour at RT. The African subjects were healthy adults, aged >18 years, and were life-long residents of Gabon, an area that has perennial transmission of Plasmodium falciparum.
An additional human serum batch containing CS antibodies M31-70 was kindly provided by Dr. Rinaldo Zurbriggen (Pevion Biotech Ltd, Bern, Switzerland), which was derived from an individual vaccinated with a virosome adjuvated malaria vaccine.
A normal human serum pool, and 20 individual normal human serum samples were obtained from Harlan Sera-lab, Nr Loughborough, UK, and were used as negative controls. All serum was heat-inactivated for 30 minutes at 56°C.
Validation
Validation was performed as per validation protocol with preset acceptance criteria. This immunogenicity assay was validated for specificity, sensitivity, precision, and linearity and range as indicated by the guidelines from the International Conference on Harmonisation (ICH) and the US Food and Drug Agency (FDA) (5, 8) . The acceptance criteria were derived from the interpretation of Viswanathan (21) for ligand binding assays. These included a maximum coefficient of variation (CV) of 20% for precision and accuracy, and 25% for samples at the lower Limit of Quantitation (LOQ), and 30%
CV for total error (bias + precision). Validation experiments were performed using six quality control samples (QC) spanning the required range of the assay. Hereto, the CS positive serum M31-70 was diluted in negative serum to obtain large batches of CS positive sera at different concentrations.
These were aliquoted and stored at -80°C, until retrieved for experimentation. The nominal titers of the QC samples were based on multiple measurements on the stock serum M31-70, corrected for the dilution in negative serum. These nominal titers and acceptance ranges are listed in Table I .
Data analysis and Statistical methods
Data were analyzed using Gen5 version 1.05. Sample titers were calculated in relation to the reference serum which was designated with a titer of 2315 ELISA units (EU/ml), as transformed to obtain a normal distribution of data. Analysis of precision and accuracy was based on non-transformed data because the applicable guidelines prescribe acceptance criteria expressed in %, which is not possible on a log scale. Means, Stdev and CV were calculated using SAS (version 9.1) command 'proc means'. Intermediate precision and reproducibility were based on the Root Mean Squared Errors of regression models (SAS command "proc glm") with the experiment and/or sample code as grouping variables.
Results
Basic assay set up
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The basic ELISA protocol as described in the materials and methods section was determined using test sera that were tested positive in other laboratories for CS specific antibodies. We optimized the peptide coating, secondary antibody manufacturer and working concentration by cross titrations of coating and secondary antibodies (data not shown).
Reference standard
The CS positive serum IR2 was selected for use as reference standard because it showed a high signal in the ELISA and because sufficient volume was available for prolonged usage. The reference standard was serially diluted in PBS, or in PBS + 1% normal human serum ( Figure 1 ). The seven successive dilutions from 1/200 to 1/12800 resulted in values above 0.2 OD, included the linear range of the response curve, and were consequently selected as calibration range.
The addition of serum to the dilution buffer had primarily an effect at the low antibody concentrations, where the background of the serum increased the OD value, compared to dilution in buffer without serum. An African serum sample A was tested in parallel and showed similar results. It was decided to test serum samples using a dilution of 1/100 and
Serum analysis of endemic, vaccinated and negative subjects
Three categories of samples were subsequently tested in the ELISA to test the applicability of the assay. Eight samples were derived from African individuals from malaria endemic regions, and four samples were derived from individuals vaccinated with candidate malaria vaccines. Ten sera were obtained from European donors to represent negative samples ( Figure 2 ). CS antibody titers could be detected in both endemic sera and vaccinated sera, whereas the presumed negative sera are all below the LOQ. These results show that the range of the ELISA is sufficient to detect both endemic antibody responses, as well as strong vaccine induced antibody responses.
Agreement with CS protein specific antibody titers
It is assumed that CS peptide binding antibodies correlate with the total CS specific antibody responses, as reported previously (4). To extend this finding to our assay set up, a selected number of samples was tested in an ELISA using recombinant CS protein as capture antigen. This CS protein batch was produced on yeast for research purposes (13), but the quantity of this protein source system however cannot be continuously guaranteed for it to be a reliable source of antigen in a standard assay. Figure 3 shows the correlation between the two techniques, although one sample clearly shows a high antibody titer against the whole protein whereas only a low titer against the repeat peptide is measured. For coating, blocking and serum incubation times, detection antibody lot number and incubation temperatures, no statistically significant differences were observed. For incubation times of the detection antibody however, a statistically significant difference was found for 1.3 and 2 hours incubation with anti-human-HRP, compared to 1, 1.5, and 2.5 hours. These differences do not follow a logical trend, however, and the observed differences cannot be avoided by restricting the incubation time. Therefore we interpret these differences as assay variation, not related to the tested incubation times. In summary, the ELISA is adequately robust, with wide ranges of acceptable incubation times.
Assay validation: Specificity
Specificity of the assay was determined by diluting QC2 twofold in five different negative serum batches. Since the Ad35 based malaria vaccine will likely induce vector specific antibodies, QC2 was also spiked in a serum sample that was positive for Ad35. A maximum bias of 20% compared to the non-treated QC2 was set as acceptance criterion.
The results corrected for the dilution factor are listed in Table II , and indicate that neither negative serum nor Ad35 positive serum introduced a bias of more than 4% in the CS specific response. 
Assay validation: Repeatability, Intermediate precision and Accuracy
Assay variation was investigated on five internal controls (QC1 through 5) in triplicate measurements in seven independent experiments. A selection of five sources of variation were introduced in the experiments, including operator, carbonate buffer lot#, blocking/sample buffer lot#, detection antibody lot# and OPD stop solution lot#. Two or three representatives were selected for each source. Acceptance criteria were set at 25%
CV for QC1 and QC5, which are close to the ULOQ or LLOQ, and 20% CV for QC2, QC3 and QC4. The repeatability, or intra-assay precision, was determined by analyzing all data obtained in the precision experiments in an ANOVA per QC samples, with assay run as fixed factor. For each QC, the mean titer, standard deviation (Stdev), and CV were calculated. As shown in Table III the repeatability CV% is within the acceptance criteria as specified above for all QC samples individually.
The intermediate precision or inter-assay variability was calculated using all data from all experiments per QC sample, thus including the assay run variability. As shown in Table   III Since a gold standard serum with a known amount of CS antibodies is not available, it is not possible to determine the absolute accuracy of the assay. Instead, we have verified whether the validation results were within the acceptance ranges based on the QC target concentrations, as determined during assay development. The overall bias towards the target concentrations of the five QC samples had to be within 25% (for QC1 and QC5, close to ULOQ and LLOQ) or 20% (for QC2, QC3 and QC4) of the nominal titer as was spiked. As shown in Table III , the bias of all internal controls are within these specifications.
Finally, the total error, which is the bias plus the intermediate precision, does not exceed 24%, which is well within the criterion of 30%.
Assay validation: Linearity
Since the QC samples were diluted from the same stock, the nominal values follow a Figure 5B shows a random distribution of data points around zero (dotted line), indicating no specific deviation from linearity. The assay is therefore considered linear in the range that has been validated in this study.
Assay validation: Stability
Although antibodies in serum matrix are generally regarded as highly stable, we investigated the stability of the QC samples under various conditions that may occur during clinical sample analysis.
To investigate the effect of freeze thaw cycles, three triplicate sets of QC1, QC3, and QC5 were subjected to one, two and three freeze thaw cycles by freezing at -80°C and thawing at room temperature. The acceptance criteria were set at a bias of 25% for QC1
and QC5, and 20% for QC3. The accuracy of the treated QC samples is plotted as on August 27, 2017 by guest http://cvi.asm.org/ Downloaded from percentage relative to the non-treated QC samples in Figure 6 . The results show no relevant differences of QC samples after 3 cycles compared to non-treated samples, therefore it is concluded that clinical samples are allowed to be reanalyzed for 3 times, provided storage at -80°C.
In addition, the stability of the samples at room temperature on the bench top for two hours after complete thawing was tested, representing the maximum processing time of samples during an assay run. The results in Figure 6 show that the samples remained stable within the acceptable range.
Assay validation: Reproducibility between different laboratories
One of the main reasons to use a simple synthetic peptide instead of a recombinant protein of limited availability is that peptides facilitate the standardization of assays across different laboratories, and enhance reproducibility between different laboratories.
To verify this, we performed the validation of the same ELISA at a different laboratory, ABL, Assen the Netherlands. For each QC sample the mean titer was calculated and these were compared with the mean QC titers obtained during the validation at Crucell.
The agreement of the two laboratory results are shown in Figure 7 .
The reproducibility between laboratories was calculated as the CV% obtained with all the precision measurements at the two laboratories together (Table IV) . Although increased variability could be expected between different laboratories, the reproducibility is comparable to the intermediate precision obtained at one laboratory alone. Indeed, we have shown highly reproducible results between two different laboratories.
Since the first report of using NANP repeat peptides as CS antigen (23) 
